Zai Lab Limited (ZLAB) is a biopharmaceutical company that focuses on the discovery, development, and commercialization of innovative medicines for unmet medical needs in China and worldwide. The company has a portfolio of product candidates in various stages of clinical development, including oncology, autoimmune, and infectious diseases. Its lead product candidate, Zejula (niraparib), is an oral, once-daily poly(ADP-ribose) polymerase (PARP) inhibitor that is approved for the treatment of ovarian cancer in China and the United States. Zai Lab has collaborations with several global pharmaceutical companies, including Novartis, Sanofi, and GlaxoSmithKline, to develop and commercialize its product candidates. The company was founded in 2014 and is headquartered in Shanghai, China.
Zai Lab Limited (ZLAB) is a biopharmaceutical company that focuses on the discovery, development, and commercialization of innovative medicines for unmet medical needs in China and worldwide. The company has a portfolio of product candidates in various stages of clinical development, including oncology, autoimmune, and infectious diseases. Its lead product candidate, Zejula (niraparib), is an oral, once-daily poly(ADP-ribose) polymerase (PARP) inhibitor that is approved for the treatment of ovarian cancer in China and the United States. Zai Lab has collaborations with several global pharmaceutical companies, including Novartis, Sanofi, and GlaxoSmithKline, to develop and commercialize its product candidates. The company was founded in 2014 and is headquartered in Shanghai, China.